Saturday, November 21, 2026 · Edition updated 6:00 AM ETSAT, NOV 21 · 6 AM ET editionNext edition in Next --:--:--

Weight management in people with HIV

A summary of earlier studies · The lancet. HIV · Nov 8, 2026

What this means

Excess weight gain in people with HIV is now recognised as a common risk associated with the use of guideline-recommended antiretroviral therapy, such that nearly 50% of people with HIV are living with comorbid obesity. Weight gain and clinical obesity exacerbate cardiovascular-kidney-metabolic health complications in this population and chronic weight management strategies that reduce these risks are now an urgent priority.

A plain-English summary is on its way. Until then, this is the start of the authors' own summary.

Tested inSummary of earlier studies
Who it was tested in
Earlier studies
Kind of research
A summary of earlier studies

The science

Original title
Weight management in people with HIV.
Authors
Manne-Goehler J, Magodoro I, Ramírez BC et al.
Journal
The lancet. HIV
Published
Nov 8, 2026
Study type
Review

Abstract

Excess weight gain in people with HIV is now recognised as a common risk associated with the use of guideline-recommended antiretroviral therapy, such that nearly 50% of people with HIV are living with comorbid obesity. Weight gain and clinical obesity exacerbate cardiovascular-kidney-metabolic health complications in this population and chronic weight management strategies that reduce these risks are now an urgent priority. Behavioural interventions can be offered to improve diet and increase physical activity, including increasing protein intake and promoting regular physical activity. Additionally, there is a growing body of evidence to support the use of GLP-1 receptor agonist therapies in people with HIV, along with a historical literature showing the efficacy of tesamorelin; however, there are sparse data to direct the use of other approved obesity management medicines specific to this population. Finally, bariatric surgical interventions are suggested to be safe and efficacious for those with chronic HIV infection and comorbid obesity. This Series paper identifies a range of key evidence gaps and research priorities for obesity management in people with HIV, including a lack of trials of GLP-1 therapies in people with HIV powered to key clinical outcomes, such as major adverse cardiovascular events and body composition endpoints, implementation science to define models of care, and research on the heterogeneities in clinical outcomes of obesity treatment by sex.

Read it on PubMed ↗

Manne-Goehler J, Magodoro I, Ramírez BC et al. Weight management in people with HIV. The lancet. HIV. 2026. doi:10.1016/S2352-3018(26)00229-8. PMID: 43000036. https://pubmed.ncbi.nlm.nih.gov/43000036/

Related research

AnimalsStudy · bioRxiv : the preprint server for biology · Nov 20, 2026

Aging exacerbates muscle loss induced by semaglutide treatment in female mice.

BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide, have transformed the pharmacological treatment of obesity.

Summary of earlier studiesReview · Journal of cosmetic dermatology · Nov 18, 2026

Review compares six collagen fillers for face loss linked to weight-loss drugs

This review looked at 43 studies of six types of collagen-building fillers and how each may signal cells. It does not show which filler works best, and no study tested people on these drugs.

AnimalsPreprint · bioRxiv · Nov 13, 2026

Aging exacerbates muscle loss induced by semaglutide treatment in female mice

Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide, have transformed the pharmacological treatment of obesity.

PeopleClinical trial · Journal of drugs in dermatology : JDD · Sep 4, 2026

A skin serum showed visible improvements in older women over 12 weeks

Women aged 45 and older used a facial serum twice a day for 12 weeks. Experts and participants saw changes in fine lines, wrinkles, and skin hydration. This study had no comparison group, so it cannot show the serum caused the changes.

Study · Journal of the American Geriatrics Society · Oct 29, 2026

Doctors' group offers a guide for using weight-loss drugs like GLP-1 in older adults

Experts wrote a guide on weighing benefits and risks, such as muscle loss, when older adults take these drugs. It is advice built from example patient cases, not a new study testing the drugs.

Summary of earlier studiesReview · Journal of the International Association of Providers of AIDS Care · Jul 31, 2026

Tesamorelin reduced belly fat in people with HIV and fat changes

Four trials with 909 people found tesamorelin lowered belly fat and waist size. Long-term safety and how long the benefit lasts are still unclear.

See all research on GLP-1 drugs →

Report a problem